Latest Share Chat

AKR.L Share News (AKR)

AKR.L Information

There is currently no data for AKR

Akers Bioscience wins first China order for heparin test

Wed, 02nd Mar 2016 13:57

(ShareCast News) - Akers Biosciences has won its first order from Chinese distributor NovoTek Therapeutics, worth $2.5m.The order is for Akers' handheld PIFA heparin allergy tests, which in November gained approval from the China Food and Drug Administration and will be exclusively sold and marketed in China by Beijing-based Novotek.With around 12m patients estimated to be prescribed heparin in China and an average of around 1-5% of patients developing the heparin-induced thrombocytopenia (HIT) for which the PIFA assays are designed to test, analysts estimated the potential demand stood at up to 0.6m tests per year."The China FDA's approval of our test paves the way for Akers Bio and NovoTek to establish the PIFA Heparin/PF4 Rapid Assay devices as the gold standard for HIT testing throughout China," said executive chairman Raymond Akers."Our partner, NovoTek, is developing a complete solution to manage HIT in the Chinese healthcare system by having the exclusive licenses both for our test as well as for a treatment for those patients who have been diagnosed with HIT."House broker FinnCap said that, against a sales base of roughly $4m the China order was "substantial".The broker explained that the order was expected to be fulfilled in tranches throughout 2016 with first sales anticipated prior to the end of the first quarter.Shares in Akers were up 13% to 110p by late afternoon on Wednesday, according to data from the London Stock Exchange.

More News

8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute with Pulse Health.

15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid assay products had offset a stronger showing in its breathalyser unit.

3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.The AIM-listed firm

16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants to

16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable markers. The US Patent and Trademark Office has given a patent for its proprietary cartridge for the optical scanning device used in the company's Brea

10 Jan 2017 12:06

Akers Biosciences to raise $2m in US placing

(ShareCast News) - Rapid diagnostic test manufacturer Akers Biosciences said it plans to issue $2m of new shares plus warrants over another $1m worth of shares. The AIM- and Nasdaq-listed outfit said funds will be used for working capital as well as to accelerate growth in the US and in internationa

19 Dec 2016 14:52

Akers Biosciences signs three year deal with US hospital group

(ShareCast News) - Rapid health information technology developer Akers Biosciences announced on Friday it has signed a three-year agreement with the Greater New York Hospital Association to introduce its flagship rapid tests for heparin-induced thrombocytopenia across the association's network of ov

12 Dec 2016 16:03

UK Shareholder Meetings Calendar - Next 7 Days

1 Dec 2016 12:13

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

10 Nov 2016 09:46

Akers Biosciences gains European patent for ketone breath device

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, gains a European patent for its ketone acid breath device. The European Patent Office has issued a patent covering the company's breath ketone detector, a breath device to monitor ketone levels, which follows

19 Aug 2016 12:18

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

(ShareCast News) - Akers Biosciences has reached a settlement agreement with former distributor ChubeWorkx Guernsey Ltd, allowing it to recover $1.25m in product and cash and end a lengthy legal dispute between the pair. ChubeWorkx would recover what it was owed from a promissory note by taking deli

18 Aug 2016 07:22

Latest Share Chat

AKR.L Share News (AKR)

Akers Bioscience wins first China order for heparin test

Akers Biosciences appoints chief executive after settling legal battle

Akers Biosciences profits hit over antigen difficulties

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

Akers Biosciences gains US patent for disposable cartridge

Akers Biosciences to raise $2m in US placing

Akers Biosciences signs three year deal with US hospital group

UK Shareholder Meetings Calendar - Next 7 Days

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

Akers Biosciences gains European patent for ketone breath device

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

Akers Says Test Results "Highly Successful" For BreathScan OxiChek

Akers Says Rapid Chlamydia Test Trial "Highly Successful"

Akers Biosciences Signs First Distribution Deal For BreathScan OxiChek

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Latest Share Chat

AKR.L Share News (AKR)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Akers Bioscience wins first China order for heparin test

Login to your account

Quickpicks are a member only feature

Login to your account